(Q24235017)

https://api.crossref.org/works/10.1002%2F14651858.CD007253.PUB2

Characteristics of smokers with a psychotic disorder and implications for smoking interventions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007253.PUB2

A pilot trial of bupropion added to cognitive behavioral therapy for smoking cessation in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007253.PUB2

A double-blind placebo-controlled trial of bupropion sustained-release for smoking cessation in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007253.PUB2

A comparison of smoking cessation treatments for persons with schizophrenia and other serious mental illnesses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007253.PUB2

A placebo controlled trial of bupropion for smoking cessation in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007253.PUB2

A placebo-controlled trial of bupropion combined with nicotine patch for smoking cessation in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007253.PUB2

A double-blind placebo-controlled cross over trial of bupropion in smoking reduction in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007253.PUB2

Transdermal nicotine and smoking behavior in psychiatric patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007253.PUB2

Motivational interviewing with personalized feedback: a brief intervention for motivating smokers with schizophrenia to seek treatment for tobacco dependence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007253.PUB2

Does clozapine decrease smoking?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007253.PUB2

Galantamine for the treatment of cognitive impairments in people with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007253.PUB2

Lack of beneficial galantamine effect for smoking behavior: a double-blind randomized trial in people with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007253.PUB2

Effects of atomoxetine on cognitive function and cigarette smoking in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007253.PUB2

A placebo-controlled, random-assignment, parallel-group pilot study of adjunctive topiramate for patients with schizoaffective disorder, bipolar type.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007253.PUB2

Effects of topiramate on smoking in patients with schizoaffective disorder, bipolar type

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007253.PUB2

Effects of Topiramate on Smoking in Patients with Schizoaffective Disorder, Bipolar Type: Response to Khazaal and Zullino

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007253.PUB2

Effects of the nicotinic receptor antagonist mecamylamine on ad-lib smoking behavior, topography, and nicotine levels in smokers with and without schizophrenia: a preliminary study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007253.PUB2

Effects of sustained-release bupropion and supportive group therapy on cigarette consumption in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007253.PUB2

The effectiveness of nicotine-patch therapy for smoking cessation in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007253.PUB2

Schizophrenia, sensory gating, and nicotinic receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007253.PUB2

Causes of the excess mortality of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007253.PUB2

The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007253.PUB2

Balancing benefits and harms in health care.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007253.PUB2

Predictors of early abstinence in smokers with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007253.PUB2

A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007253.PUB2

Smoking in patients receiving psychotropic medications: a pharmacokinetic perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007253.PUB2

Dual diagnosis of substance abuse in schizophrenia: prevalence and impact on outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007253.PUB2

Effects of smoking on fluphenazine clearance in psychiatric inpatients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007253.PUB2

Epidemiology of tobacco use in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007253.PUB2

Cigarette smoking in schizophrenia: relationship to psychopathology and medication side effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007253.PUB2

Operant Conditioning of Activities of Daily Living on a Psychogeriatric Ward: A Simple Method

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007253.PUB2

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007253.PUB2

The feasibility of smoking reduction: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007253.PUB2

Does smoking reduction increase future cessation and decrease disease risk? A qualitative review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007253.PUB2

Antidepressants for smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007253.PUB2

Recent advances in the development of treatments for alcohol and cocaine dependence: focus on topiramate and other modulators of GABA or glutamate function

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007253.PUB2

The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2009.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007253.PUB2

Effects of typical and atypical antipsychotics on prepulse inhibition in schizophrenia: a critical evaluation of current evidence and directions for future research

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007253.PUB2

Individual behavioural counselling for smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007253.PUB2

Self-help interventions for smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007253.PUB2

Incidence of cancer among persons with schizophrenia and their relatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007253.PUB2

Prefrontal cognitive dysfunction is associated with tobacco dependence treatment failure in smokers with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007253.PUB2

Increased levels of the nicotine metabolite cotinine in schizophrenic smokers compared to other smokers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007253.PUB2

Current models of nicotine dependence: what is known and what is needed to advance understanding of tobacco etiology among youth

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007253.PUB2

Changes in psychiatric patients' thoughts about quitting smoking during a smoke-free hospitalization

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007253.PUB2

Group behaviour therapy programmes for smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007253.PUB2

Physician advice for smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007253.PUB2

Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007253.PUB2

Outcome criteria in smoking cessation trials: proposal for a common standard.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007253.PUB2

Increased nicotine and cotinine levels in smokers with schizophrenia and schizoaffective disorder is not a metabolic effect.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007253.PUB2

Smoking restrictions and treatment for smoking: policies and procedures in psychiatric inpatient units in Australia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007253.PUB2

Efficacy and safety of bupropion for smoking cessation and reduction in schizophrenia: systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007253.PUB2

Telephone counselling for smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007253.PUB2

7 January 2021

Haloperidol increases smoking in patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007253.PUB2

7 January 2021

Clozapine decreases smoking in patients with chronic schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007253.PUB2

7 January 2021

Smoking and therapeutic response to clozapine in patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007253.PUB2

7 January 2021

Nicotine withdrawal and psychiatric symptoms in cigarette smokers with schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007253.PUB2

7 January 2021

Contingent monetary reinforcement of smoking reductions, with and without transdermal nicotine, in outpatients with schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007253.PUB2

7 January 2021

Use of monetary reinforcement to reduce the cigarette smoking of persons with schizophrenia: a feasibility study.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007253.PUB2

7 January 2021

Acute feasibility and safety of a smoking reduction strategy for smokers with schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007253.PUB2

7 January 2021

A 12-week double-blind, placebo-controlled study of bupropion sr added to high-dose dual nicotine replacement therapy for smoking cessation or reduction in schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007253.PUB2

7 January 2021

Nicotine transdermal patch and atypical antipsychotic medications for smoking cessation in schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007253.PUB2

7 January 2021

Two-year follow-up of a smoking cessation trial in patients with schizophrenia: increased rates of smoking cessation and reduction

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007253.PUB2

7 January 2021

Independent effects of tobacco abstinence and bupropion on cognitive function in schizophrenia.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007253.PUB2

7 January 2021